Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Hepatol
    October 2023
  1. GROBA SR, Soehnlein O
    DRANquilizing neutrophil function in chronic liver disease.
    J Hepatol. 2023;79:885-887.
    >> Share

  2. ROMERO-GOMEZ M, Lawitz E, Shankar RR, Chaudhri E, et al
    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2023;79:888-897.
    >> Share

  3. LI L, Wang Z, Jiang Y
    Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again.
    J Hepatol. 2023;79:e164-e165.
    >> Share

  4. GUO R, Xu X, Babcock SA, Zhang Y, et al
    Retraction notice to "Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy" [J Hepatol 62 (3) (2015) 647-656].
    J Hepatol. 2023;79:1072.
    >> Share

    September 2023

  5. Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
    J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
    >> Share

  6. LALEMAN W, Vanderschueren E, Mehdi ZS, Wiest R, et al
    Endoscopic procedures in HEPATOLOGY:CURRENT trends and new developments.
    J Hepatol. 2023 Sep 18:S0168-8278(23)05101-2. doi: 10.1016/j.jhep.2023.
    >> Share


  7. Corrigendum to "EASL clinical practice guidelines on the management of cystic liver diseases" [J Hepatol (77) 1083-1108].
    J Hepatol. 2023 Sep 17:S0168-8278(23)05089-4. doi: 10.1016/j.jhep.2023.
    >> Share

  8. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    >> Share

  9. CHEN X, Chen S, Pang J, Huang R, et al
    Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.
    J Hepatol. 2023 Sep 5:S0168-8278(23)05077-8. doi: 10.1016/j.jhep.2023.
    >> Share

  10. WANG Q, Bu Q, Zhou H, Lu L, et al
    Reply to?"Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis".
    J Hepatol. 2023 Sep 4:S0168-8278(23)05076-6. doi: 10.1016/j.jhep.2023.
    >> Share


  11. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy.
    J Hepatol. 2023;79:768-828.
    >> Share

  12. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
    A global research priority agenda to advance public health responses to fatty liver disease.
    J Hepatol. 2023;79:618-634.
    >> Share

  13. FUNDORA Y, Hessheimer AJ, Fondevila C
    Reply to: "Reconstruction for complex portal vein thrombosis - Anatomical if possible".
    J Hepatol. 2023;79:e131-e133.
    >> Share

  14. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    >> Share

  15. BOURSIER J, Roux M, Sanyal AJ
    Reply to: "Agile scores are a good predictor of liver-related events in patients with NAFLD".
    J Hepatol. 2023;79:e128-e129.
    >> Share

  16. HARRISON SA, Ratziu V, Magnanensi J, Hajji Y, et al
    NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study.
    J Hepatol. 2023;79:758-767.
    >> Share

  17. WONG VW, Ekstedt M, Wong GL, Hagstrom H, et al
    Changing epidemiology, global trends and implications for outcomes of NAFLD.
    J Hepatol. 2023;79:842-852.
    >> Share

  18. LIANG JX, Ampuero J, Niu H, Imajo K, et al
    An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
    J Hepatol. 2023;79:592-604.
    >> Share

  19. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    >> Share

  20. DURAN M, Alfarah J, Hann A, Perera MTPR, et al
    Reconstruction for complex portal vein thrombosis - Anatomical if possible.
    J Hepatol. 2023;79:e129-e131.
    >> Share

  21. NAKATSUKA T, Tateishi R, Sato M, Fujishiro M, et al
    Agile scores are a good predictor of liver-related events in patients with NAFLD.
    J Hepatol. 2023;79:e126-e127.
    >> Share

    August 2023
  22. EBRAHIMI F, Hagstrom H, Sun J, Bergman D, et al
    Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05071-7. doi: 10.1016/j.jhep.2023.
    >> Share

  23. LIMOUSIN W, Laurent-Puig P, Ziol M, Ganne-Carrie N, et al
    Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05070-5. doi: 10.1016/j.jhep.2023.
    >> Share

  24. BALLESTER MP, Carbonell-Asins JA, Balcar L, Reiberger T, et al
    Reply to: Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Aug 23:S0168-8278(23)05068-7. doi: 10.1016/j.jhep.2023.
    >> Share

  25. CAI J, Wang J, Jiang C, Ye L, et al
    Combined inhibition of surface CD51 and gamma-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma.
    J Hepatol. 2023 Aug 19:S0168-8278(23)05062-6. doi: 10.1016/j.jhep.2023.
    >> Share

  26. WAN YM, Wu HM, Huang SQ, Li HY, et al
    A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B." (J Hepatol. 2023 May;78(5):926-936.).
    J Hepatol. 2023 Aug 11:S0168-8278(23)05051-1. doi: 10.1016/j.jhep.2023.
    >> Share

  27. UPADHYAY KK, Du X, Chen Y, Buscher B, et al
    A common variant that alters SUN1 degradation associates with hepatic steatosis and metabolic traits in multiple cohorts.
    J Hepatol. 2023 Aug 9:S0168-8278(23)05049-3. doi: 10.1016/j.jhep.2023.
    >> Share

  28. ZANETTO A, Pelizzaro F, Bellan E, Sbaraglia M, et al
    Multiple hepatic cysts in an adult male.
    J Hepatol. 2023;79:e64-e66.
    >> Share

  29. RATZIU V, Tacke F
    At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH.
    J Hepatol. 2023;79:261-262.
    >> Share

  30. TSOCHATZIS EA
    Screening for liver fibrosis - sequential non-invasive testing works best.
    J Hepatol. 2023;79:263-265.
    >> Share

  31. KOTSILITI E, Leone V, Schuehle S, Govaere O, et al
    Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    J Hepatol. 2023;79:296-313.
    >> Share

  32. FERNANDEZ-CHECA JC, Torres S, Garcia-Ruiz C
    HILPDA, a new player in NASH-driven HCC, links hypoxia signaling with ceramide synthesis.
    J Hepatol. 2023;79:269-272.
    >> Share

  33. SINGAL AG, Marrero J, Parikh ND
    Reply to: "Correction for length bias reduces the mortality benefit from hepatocellular carcinoma surveillance".
    J Hepatol. 2023;79:e90-e92.
    >> Share

  34. ROMA K, Mohammed S, Sieck B, Naik K, et al
    Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
    J Hepatol. 2023;79:581-584.
    >> Share

  35. MOHR I, Pfeiffenberger J, Eker E, Merle U, et al
    Neurological worsening in Wilson disease - clinical classification and outcome.
    J Hepatol. 2023;79:321-328.
    >> Share

  36. KJAERGAARD M, Lindvig KP, Thorhauge KH, Andersen P, et al
    Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    J Hepatol. 2023;79:277-286.
    >> Share

  37. MEYER T, Galani S, Lopes A, Vogel A, et al
    Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease.
    J Hepatol. 2023;79:e73-e76.
    >> Share

  38. POVERO D, Chen Y, Johnson SM, McMahon CE, et al
    HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
    J Hepatol. 2023;79:378-393.
    >> Share

  39. TACKE F, Puengel T, Loomba R, Friedman SL, et al
    An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    J Hepatol. 2023;79:552-566.
    >> Share

  40. LE MH, Le DM, Baez TC, Wu Y, et al
    Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.
    J Hepatol. 2023;79:287-295.
    >> Share

  41. AYYALA-SOMAYAJULA D, Dodge JL, Farias A, Terrault N, et al
    Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States.
    J Hepatol. 2023;79:329-339.
    >> Share

  42. YAHOO N, Dudek M, Knolle P, Heikenwalder M, et al
    Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
    J Hepatol. 2023;79:538-551.
    >> Share

  43. BAROUKI R, Samson M, Blanc EB, Colombo M, et al
    The exposome and liver disease - how environmental factors affect liver health.
    J Hepatol. 2023;79:492-505.
    >> Share

  44. PENG J, Lu M, Peng Y, Tang X, et al
    Global incidence of primary liver cancer by etiology among children, adolescents, and young adults.
    J Hepatol. 2023;79:e92-e94.
    >> Share

    July 2023
  45. PATIDAR KR, Belcher JM, Regner KR, St Hillien SA, et al
    Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04990-5. doi: 10.1016/j.jhep.2023.
    >> Share

  46. SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
    Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
    >> Share

  47. TAPPER EB, Bajaj JS
    Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05003-1. doi: 10.1016/j.jhep.2023.
    >> Share

  48. VUKOTIC R, Di Donato R, Roncarati G, Simoni P, et al
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
    J Hepatol. 2023 Jul 21:S0168-8278(23)04940-1. doi: 10.1016/j.jhep.2023.
    >> Share

  49. KUTER DJ, Bonkovsky HL, Monroy S, Ross G, et al
    Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
    J Hepatol. 2023 Jul 19:S0168-8278(23)04933-4. doi: 10.1016/j.jhep.2023.
    >> Share

  50. LU Y, Sun Q, Guan Q, Zhang Z, et al
    The XOR-IDH3alpha axis controls macrophage polarization in hepatocellular carcinoma.
    J Hepatol. 2023 Jul 18:S0168-8278(23)04984-X. doi: 10.1016/j.jhep.2023.
    >> Share

  51. SONG Q, Zhang X, Liu W, Wei H, et al
    Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    J Hepatol. 2023 Jul 15:S0168-8278(23)04981-4. doi: 10.1016/j.jhep.2023.
    >> Share

  52. GUAN MC, Ding Q, Zhu H
    Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over one year ?
    J Hepatol. 2023 Jul 4:S0168-8278(23)04937-1. doi: 10.1016/j.jhep.2023.
    >> Share

  53. AGARWAL B, Canizares RB, Saliba F, Ballester MP, et al
    Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
    J Hepatol. 2023;79:79-92.
    >> Share


  54. A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD.
    J Hepatol. 2023;79:4-5.
    >> Share

  55. CRAIG AJ, Silveira MAD
    The role of ETV4 in HCC: How transcription factors can inform immunotherapy combination treatments.
    J Hepatol. 2023;79:19-21.
    >> Share

  56. ROWE IA
    Understanding the risks and benefits of policy action in NAFLD.
    J Hepatol. 2023;79:22-24.
    >> Share

  57. BERAZA N
    Ketohexokinase-C: The mechanistic link between dietary sugars and protein acetylation during liver steatosis.
    J Hepatol. 2023;79:16-18.
    >> Share

  58. D'ARTISTA L, Moschopoulou AA, Barozzi I, Craig AJ, et al
    MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    J Hepatol. 2023;79:141-149.
    >> Share

  59. HACKSTEIN CP, Spitzer J, Symeonidis K, Horvatic H, et al
    Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
    J Hepatol. 2023;79:150-166.
    >> Share

  60. VILLANUEVA C, Torres F, Tripathi D, Bosch J, et al
    Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
    J Hepatol. 2023;79:e23-e24.
    >> Share

  61. NAHON P, Trepo E
    Reply to: "Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses".
    J Hepatol. 2023;79:e35-e37.
    >> Share

  62. SCHEINER B, Balcar L, Lisman T, Mandorfer M, et al
    Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'.
    J Hepatol. 2023;79:e27-e28.
    >> Share

  63. ALLEN AM, Lazarus JV, Younossi ZM
    Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.
    J Hepatol. 2023;79:209-217.
    >> Share

  64. PONZIANI FR, Santopaolo F, Gasbarrini A, De Cristofaro R, et al
    From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?
    J Hepatol. 2023;79:e25-e27.
    >> Share

  65. RIDOLA L, Riggio O
    Comment to: "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.".
    J Hepatol. 2023 Jul 1:S0168-8278(23)04938-3. doi: 10.1016/j.jhep.2023.
    >> Share

  66. LI Z, Hu Y, Zou B
    The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
    J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  67. AGRAWAL D, Ariga KK
    Target mean arterial pressure in critically ill cirrhotic patients with septic shock: More is not always better!
    J Hepatol. 2023 Jun 29:S0168-8278(23)04931-0. doi: 10.1016/j.jhep.2023.
    >> Share

  68. YANG H, Kim JH, Han JW, Lee SK, et al
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?'.
    J Hepatol. 2023 Jun 27:S0168-8278(23)00425-7. doi: 10.1016/j.jhep.2023.
    >> Share

  69. CASSANO SANTOS U, Coelho de Souza MDG, Ferreira da Motta Rezende G
    Selection of patients with portal hypertension and cirrhosis with real benefit of beta-blockers: still a current challenge.
    J Hepatol. 2023 Jun 26:S0168-8278(23)00428-2. doi: 10.1016/j.jhep.2023.
    >> Share

  70. NAYAGAM JS, Masson S, Ferguson JW, Griffiths W, et al
    Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?
    J Hepatol. 2023 Jun 26:S0168-8278(23)00429-4. doi: 10.1016/j.jhep.2023.
    >> Share

  71. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    >> Share

  72. ZHANG X, Sharma P, Maschmeyer P, Hu Y, et al
    GARP on hepatic stellate cells is essential for the development of liver fibrosis.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00422-1. doi: 10.1016/j.jhep.2023.
    >> Share

  73. ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
    Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
    >> Share

  74. TAVABIE O
    Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
    J Hepatol. 2023 Jun 12:S0168-8278(23)00413-0. doi: 10.1016/j.jhep.2023.
    >> Share

  75. BERTOLETTI A, Le Bert N, Tan AT, Boni C, et al
    End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB, by Huang et al. J Hepatology 77, 42-54 (2022).
    J Hepatol. 2023 Jun 10:S0168-8278(23)00408-7. doi: 10.1016/j.jhep.2023.
    >> Share

  76. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    >> Share

  77. CLAVERIA-CABELLO A, Herranz JM, Latasa MU, Arechederra M, et al
    Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00405-1. doi: 10.1016/j.jhep.2023.
    >> Share

  78. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    >> Share

  79. ELKRIEF L, Ganne-Carrie N, Manceau H, Tanguy M, et al
    Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00401-4. doi: 10.1016/j.jhep.2023.
    >> Share

  80. LIU X, Wen X, Lu F
    Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
    J Hepatol. 2023 Jun 9:S0168-8278(23)00402-6. doi: 10.1016/j.jhep.2023.
    >> Share

  81. SENZOLO M, Garcia-Pagan JC
    A major research gap: the use of anticoagulants in cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00407-5. doi: 10.1016/j.jhep.2023.
    >> Share

  82. FU W, Liu C, Li J
    Short-term activation of PERK alleviates the progression of experimental nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jun 8:S0168-8278(23)00411-7. doi: 10.1016/j.jhep.2023.
    >> Share

  83. ALBILLOS A, Guerrero A, Tellez L
    Reply to: "Anticoagulation to prevent disease progression in patients with cirrhosis".
    J Hepatol. 2023 Jun 8:S0168-8278(23)00414-2. doi: 10.1016/j.jhep.2023.
    >> Share

  84. RAEVENS S, Fallon MB
    Fingolimod as a sphingolipid modulator in hepatopulmonary syndrome: a critical review.
    J Hepatol. 2023 Jun 8:S0168-8278(23)00406-3. doi: 10.1016/j.jhep.2023.
    >> Share

  85. FONDEVILA MF, Schnabl B
    Intestinal clock modulates rhythmic hepatic metabolism.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00350-1. doi: 10.1016/j.jhep.2023.
    >> Share

  86. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
    J Hepatol. 2023 Jun 3:S0168-8278(23)00351-3. doi: 10.1016/j.jhep.2023.
    >> Share

  87. SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
    Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
    J Hepatol. 2023;78:1124-1129.
    >> Share

  88. BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
    Artificial intelligence, machine learning, and deep learning in liver transplantation.
    J Hepatol. 2023;78:1216-1233.
    >> Share

  89. KASAHARA M, Hong JC, Dhawan A
    Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
    J Hepatol. 2023;78:1147-1156.
    >> Share

  90. CLIFT AK, Hagness M, Lehmann K, Rosen CB, et al
    Transplantation for metastatic liver disease.
    J Hepatol. 2023;78:1137-1146.
    >> Share

  91. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    >> Share

  92. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    >> Share

  93. TSOCHATZIS EA, Watt KD, VanWagner LB, Verna EC, et al
    Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease.
    J Hepatol. 2023;78:1089-1104.
    >> Share

  94. BURRA P
    The changing world of liver transplantation.
    J Hepatol. 2023;78:1087-1088.
    >> Share

    May 2023
  95. LALLOYER F, Mogilenko DA, Verrijken A, Haas JT, et al
    Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis.
    J Hepatol. 2023 May 23:S0168-8278(23)00341-0. doi: 10.1016/j.jhep.2023.
    >> Share

  96. HE F, Jiang H, Peng C, Wang T, et al
    Hepatic glucuronyl C5-epimerase combats obesity by stabilizing GDF15.
    J Hepatol. 2023 May 20:S0168-8278(23)00340-9. doi: 10.1016/j.jhep.2023.
    >> Share

  97. INNES H, Nahon P
    Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
    J Hepatol. 2023 May 18:S0168-8278(23)00334-3. doi: 10.1016/j.jhep.2023.
    >> Share

  98. LINDEN D, Romeo S
    Mini-Review for Journal of HepatologyTherapeutic opportunities for the treatment of NASH with genetically validated targets.
    J Hepatol. 2023 May 17:S0168-8278(23)00335-5. doi: 10.1016/j.jhep.2023.
    >> Share

  99. SCHAEFFER S, Gupta B, Calatayud AL, Calderaro J, et al
    RSK2 inactivation cooperates with AXIN1 inactivation or ss-catenin activation to promote hepatocarcinogenesis.
    J Hepatol. 2023 May 16:S0168-8278(23)00333-1. doi: 10.1016/j.jhep.2023.
    >> Share

  100. SHAWCROSS DL, Thabut D, Amodio P
    Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
    J Hepatol. 2023 May 11:S0168-8278(23)00327-6. doi: 10.1016/j.jhep.2023.
    >> Share

  101. ZHANG C, Ding WX
    Caveats to link in vitro mechanistic mitophagy studies to the pathogenesis of non-alcoholic steatohepatitis.
    J Hepatol. 2023 May 6:S0168-8278(23)00319-7. doi: 10.1016/j.jhep.2023.
    >> Share

  102. ASHRAF MU, De A, Rose S
    Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns.
    J Hepatol. 2023 May 3:S0168-8278(23)00315-X. doi: 10.1016/j.jhep.2023.
    >> Share

  103. LARRUE H, D'Amico G, Olivas P, Lv Y, et al
    TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
    J Hepatol. 2023 May 2:S0168-8278(23)00314-8. doi: 10.1016/j.jhep.2023.
    >> Share

  104. YIN JL, Ala A, Miquel R
    Histology - further raising the diagnostic bar in chronic liver disease.
    J Hepatol. 2023;78:e162-e164.
    >> Share

  105. FUNDORA Y, Fuster-Anglada C, Bassaganyas C, Toapanta D, et al
    An infrequent cause of spontaneous liver rupture.
    J Hepatol. 2023;78:e160-e161.
    >> Share

  106. DI MARTINO V
    Methotrexate-induced liver fibrosis: The end of a long-held belief.
    J Hepatol. 2023;78:896-897.
    >> Share

  107. HARRISON SA, Thang C, Bolze S, Dewitt S, et al
    Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    J Hepatol. 2023;78:914-925.
    >> Share

  108. LEE E, Korf H, Vidal-Puig A
    An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.
    J Hepatol. 2023;78:1048-1062.
    >> Share

  109. ZHANG CJ, Meyer SR, O'Meara MJ, Huang S, et al
    A human liver organoid screening platform for DILI risk prediction.
    J Hepatol. 2023;78:998-1006.
    >> Share

  110. AJMERA V, Loomba R
    Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues".
    J Hepatol. 2023;78:e168-e169.
    >> Share

  111. FALKEVALL A, Mehlem A, Folestad E, Ning FC, et al
    Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
    J Hepatol. 2023;78:901-913.
    >> Share

  112. ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
    Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
    J Hepatol. 2023;78:989-997.
    >> Share

  113. SURIAL B, Ramirez Mena A, Roumet M, Limacher A, et al
    External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
    J Hepatol. 2023;78:947-957.
    >> Share

  114. RATZIU V, Charlton M
    Rational combination therapy for NASH: Insights from clinical trials and error.
    J Hepatol. 2023;78:1073-1079.
    >> Share

  115. BINET Q, Hermans MP, Lanthier N
    Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues.
    J Hepatol. 2023;78:e166-e167.
    >> Share

  116. ZHANG H, Peng Y, Tang X
    Comment on: Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
    J Hepatol. 2023;78:e177-e178.
    >> Share

  117. DALY AK, Bjornsson ES, Lucena MI, Andrade RJ, et al
    Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
    J Hepatol. 2023;78:e165-e166.
    >> Share

    April 2023
  118. BERG T, Krag A
    The future of hepatology - "The best way to predict your future is to create it".
    J Hepatol. 2023 Apr 28:S0168-8278(23)00308-2. doi: 10.1016/j.jhep.2023.
    >> Share

  119. MAIWALL R, Rao Pasupuleti SS, Hidam AK, Kumar A, et al
    A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00229-5. doi: 10.1016/j.jhep.2023.
    >> Share

  120. PASSMAN AM, Haughey MJ, Carlotti E, Williams MJ, et al
    Hepatocytes undergo punctuated expansion dynamics from a periportal stem cell niche in normal human liver.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00223-4. doi: 10.1016/j.jhep.2023.
    >> Share

  121. AGUILAR-BRAVO B, Arino S, Blaya D, Pose E, et al
    Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00236-2. doi: 10.1016/j.jhep.2023.
    >> Share

  122. GUO Z, Zhao Q, Jia Z, Huang C, et al
    A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
    J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
    >> Share

  123. GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
    The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
    J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
    >> Share

  124. YI H, Leng Q, Zhou J, Peng S, et al
    Do open access articles have a citation advantage in Journal of Hepatology?
    J Hepatol. 2023 Apr 19:S0168-8278(23)00238-6. doi: 10.1016/j.jhep.2023.
    >> Share

  125. ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
    Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
    J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
    >> Share

  126. JIN K, Shi Y, Zhang H, Zhangyuan G, et al
    A TNFalpha/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis.
    J Hepatol. 2023 Apr 9:S0168-8278(23)00215-5. doi: 10.1016/j.jhep.2023.
    >> Share

  127. VERMA N, Garg P, Bhardwaj A, Sarohi V, et al
    Candida leucine aminopeptidase: a novel mycoprotein linked to invasive candidiasis and mortality in acutely decompensated cirrhosis.
    J Hepatol. 2023 Apr 8:S0168-8278(23)00216-7. doi: 10.1016/j.jhep.2023.
    >> Share

  128. YEOH BS, Vijay-Kumar M
    Gut microbiota lends a helping hand to nurse liver regeneration.
    J Hepatol. 2023;78:681-683.
    >> Share

  129. LIU Y, Xun Z, Ma K, Liang S, et al
    Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    J Hepatol. 2023;78:770-782.
    >> Share

  130. HADJIHAMBI A, Pellerin L
    Reply to: "Is NAFLD a key driver of brain dysfunction?".
    J Hepatol. 2023;78:e130-e131.
    >> Share

  131. RASMUSSEN DGK, Anstee QM, Torstenson R, Golding B, et al
    NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
    J Hepatol. 2023;78:852-865.
    >> Share

  132. LI C, He WQ
    Global prediction of primary liver cancer incidences and mortality in 2040.
    J Hepatol. 2023;78:e144-e146.
    >> Share

  133. WANG Y, Wang Y, Duan G, Yang H, et al
    NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: A meta-analysis.
    J Hepatol. 2023;78:e136-e139.
    >> Share

  134. SANDFORTH L, El-Agroudy NN, Birkenfeld AL
    Is NAFLD a key driver of brain dysfunction?
    J Hepatol. 2023;78:e129-e130.
    >> Share

  135. CHUNG DH, Zheng M, Bale AE, Vilarinho S, et al
    Hepatology Genome Rounds: An interdisciplinary approach to integrate genomic data in clinical practice.
    J Hepatol. 2023 Apr 1:S0168-8278(23)00208-8. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  136. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    >> Share

  137. PAIS R, Cariou B, Noureddin M, Francque S, et al
    A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials.
    J Hepatol. 2023 Mar 29:S0168-8278(23)00189-7. doi: 10.1016/j.jhep.2023.
    >> Share

  138. BAWEJA S, Kumari A, Negi P, Tomar A, et al
    Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00192-7. doi: 10.1016/j.jhep.2023.
    >> Share

  139. HE F, Zhang P, Liu J, Wang R, et al
    ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00193-9. doi: 10.1016/j.jhep.2023.
    >> Share

  140. LISMAN T, Bernal W, Luyendyk JP
    Anticoagulation to prevent disease progression in patients with cirrhosis.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00198-8. doi: 10.1016/j.jhep.2023.
    >> Share

  141. JAGADISAN B, Dhawan A
    Multidisciplinary approach and reactive immunosuppression for gene therapy related hepatotoxicity.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00197-6. doi: 10.1016/j.jhep.2023.
    >> Share


  142. EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
    >> Share

  143. MANGINI C, Gagliardi R, Causin F, Angeli P, et al
    Letter to the Editor: An isolated insular stroke mimics a bout of overt hepatic encephalopathy in a patient with cirrhosis.
    J Hepatol. 2023 Mar 19:S0168-8278(23)00179-4. doi: 10.1016/j.jhep.2023.
    >> Share

  144. RIMASSA L, Finn RS, Sangro B
    Combination immunotherapy for hepatocellular carcinoma.
    J Hepatol. 2023 Mar 16:S0168-8278(23)00178-2. doi: 10.1016/j.jhep.2023.
    >> Share

  145. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆)" [J Hepatol (2020) 505-515].
    J Hepatol. 2023 Mar 13:S0168-8278(23)00160-5. doi: 10.1016/j.jhep.2023.
    >> Share

  146. STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
    Corrigendum to "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease" [J Hepatol 77 (2022) 918-930].
    J Hepatol. 2023 Mar 13:S0168-8278(23)00030-2. doi: 10.1016/j.jhep.2023.
    >> Share

  147. XIE M, Lin Z, Ji X, Luo X, et al
    FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    J Hepatol. 2023 Mar 10:S0168-8278(23)00172-1. doi: 10.1016/j.jhep.2023.
    >> Share

  148. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    >> Share

  149. VIOLI F, Pignatelli P, Cammisotto V
    Platelet defetcts in cirrhosis: fact or fiction?
    J Hepatol. 2023 Mar 8:S0168-8278(23)00173-3. doi: 10.1016/j.jhep.2023.
    >> Share

  150. TAN J, Fan W, Liu T, Zhu B, et al
    TREM2(+) macrophages suppress CD8(+) T cell infiltration after transarterial chemoembolization in hepatocellular carcinoma.
    J Hepatol. 2023 Mar 6:S0168-8278(23)00164-2. doi: 10.1016/j.jhep.2023.
    >> Share

  151. NOGUEIRAS R, Aspichueta P
    Expanding the roles of the renin-angiotensin system: Drug-induced liver injury.
    J Hepatol. 2023;78:457-459.
    >> Share

  152. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    >> Share

  153. TROVATO FM, Zia R, Artru F, Mujib S, et al
    Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure.
    J Hepatol. 2023;78:558-573.
    >> Share

  154. BANTEL H, Schulze-Osthoff K
    Non-invasive tests for evaluating treatment response in NAFLD.
    J Hepatol. 2023;78:e101-e102.
    >> Share

  155. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    >> Share

  156. DURAND F, Kellum JA, Nadim MK
    Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00113-7. doi: 10.1016/j.jhep.2023.
    >> Share

  157. LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
    Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
    >> Share

    February 2023
  158. GUERRERO A, Campo LD, Piscaglia F, Scheiner B, et al
    Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
    J Hepatol. 2023 Feb 27:S0168-8278(23)00112-5. doi: 10.1016/j.jhep.2023.
    >> Share

  159. SINGAL AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, et al
    International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.
    J Hepatol. 2023 Feb 26:S0168-8278(23)00111-3. doi: 10.1016/j.jhep.2023.
    >> Share

  160. ZENG L, Li X, Peng Z
    Genetic variants improve hepatocellular carcinoma risk stratification, only in alcoholic cirrhosis patients?
    J Hepatol. 2023 Feb 22:S0168-8278(23)00102-2. doi: 10.1016/j.jhep.2023.
    >> Share

  161. ROBINS CJG, Buchanan RM
    Correction for length bias reduces the mortality benefit from Hepatocellular Carcinoma surveillance.
    J Hepatol. 2023 Feb 21:S0168-8278(23)00104-6. doi: 10.1016/j.jhep.2023.
    >> Share

  162. HOARE M
    Mouse models of hepatocyte biology - known unknowns.
    J Hepatol. 2023 Feb 11:S0168-8278(23)00088-0. doi: 10.1016/j.jhep.2023.
    >> Share

  163. EBADI M, Burra P, Zanetto A, Montano-Loza AJ, et al
    Current Treatment Strategies and Future Possibilities for Sarcopenia in Cirrhosis.
    J Hepatol. 2023 Feb 10:S0168-8278(23)00090-9. doi: 10.1016/j.jhep.2023.
    >> Share

  164. FABRELLAS N, Kunzler-Heule P, Olofson A, Jack K, et al
    Nursing Care For Patients With Cirrhosis.
    J Hepatol. 2023 Feb 6:S0168-8278(23)00082-X. doi: 10.1016/j.jhep.2023.
    >> Share

  165. YUEN VW, Chiu DK, Law CT, Cheu JW, et al
    Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    J Hepatol. 2023;78:376-389.
    >> Share

  166. KISHORE SB, Lewindon P, Noble C, Balouch F, et al
    Enoxaparin is safe and effective for restoring and preserving forward portal venous flow in children with end-stage liver disease.
    J Hepatol. 2023;78:e57-e59.
    >> Share

  167. LI Z, Zhang B, Li J, Tao Z, et al
    Assessing causal relationship between non-alcoholic fatty liver disease and risk of atrial fibrillation.
    J Hepatol. 2023;78:e63-e65.
    >> Share

  168. STAUFER K, Mangal B, Trauner M
    Detection of unreported alcohol consumption in fatty liver disease.
    J Hepatol. 2023;78:e67-e69.
    >> Share

  169. ROEHLEN N, Muller M, Nehme Z, Crouchet E, et al
    Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
    J Hepatol. 2023;78:343-355.
    >> Share

  170. FROMENTY B, Roden M
    Mitochondrial alterations in fatty liver diseases.
    J Hepatol. 2023;78:415-429.
    >> Share

  171. BERASAIN C, Arechederra M, Argemi J, Fernandez-Barrena MG, et al
    Loss of liver function in chronic liver disease: An identity crisis.
    J Hepatol. 2023;78:401-414.
    >> Share

  172. PARADIS V, Zucman-Rossi J
    Pathogenesis of primary liver carcinomas.
    J Hepatol. 2023;78:448-449.
    >> Share

  173. HAGSTROM H, Ekstedt M
    Considerations in the search for under-reported alcohol consumption in NAFLD.
    J Hepatol. 2023;78:e66-e67.
    >> Share

  174. CARLSON S, Vaz K, Peterson A
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?
    J Hepatol. 2023 Feb 1:S0168-8278(23)00074-0. doi: 10.1016/j.jhep.2023.
    >> Share

    January 2023
  175. SPOSITO C, Cucchetti A, Mazzaferro V
    Survival Benefit Of Lymphadenectomy For Intrahepatic Cholangiocarcinoma: It Might Be Gold Even If It Does Not Glitter.
    J Hepatol. 2023 Jan 31:S0168-8278(23)00073-9. doi: 10.1016/j.jhep.2023.
    >> Share

  176. ZANETTO A, Northup P, Roberts L, Senzolo M, et al
    Hemostasis in cirrhosis: understanding destabilising factors during acute decompensation.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00022-3. doi: 10.1016/j.jhep.2023.
    >> Share

  177. MAY S, Muller M, Livingstone CR, Skalka GL, et al
    Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration.
    J Hepatol. 2023 Jan 23:S0168-8278(23)00021-1. doi: 10.1016/j.jhep.2023.
    >> Share

  178. FUNDORA Y, Hessheimer AJ, Del Prete L, Maroni L, et al
    Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis.
    J Hepatol. 2023 Jan 20:S0168-8278(23)00018-1. doi: 10.1016/j.jhep.2023.
    >> Share

  179. YIN Y, Sichler A, Ecker J, Laschinger M, et al
    Gut microbiota promote liver regeneration through hepatic membrane phospholipid biosynthesis.
    J Hepatol. 2023 Jan 18:S0168-8278(23)00009-0. doi: 10.1016/j.jhep.2022.
    >> Share

  180. JI R, Chen J, Xie Y, Dou X, et al
    Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
    J Hepatol. 2023 Jan 18:S0168-8278(23)00015-6. doi: 10.1016/j.jhep.2022.
    >> Share

  181. TAO L, Yang G, Sun T, Tao J, et al
    Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00013-2. doi: 10.1016/j.jhep.2022.
    >> Share

  182. SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
    3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
    >> Share

  183. JI D, Tan L, Yang Y
    Reply to "Biejia-Ruangan compound and incidence of hepatocellular carcinoma".
    J Hepatol. 2023 Jan 13:S0168-8278(23)00008-9. doi: 10.1016/j.jhep.2023.
    >> Share

  184. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581].
    J Hepatol. 2023 Jan 11:S0168-8278(22)03321-9. doi: 10.1016/j.jhep.2022.
    >> Share

  185. POVERO D
    Novel oncometabolites and metabolic checkpoints involved in hepatocellular carcinoma development.
    J Hepatol. 2023 Jan 11:S0168-8278(23)00001-6. doi: 10.1016/j.jhep.2023.
    >> Share

  186. MAGYAR CTJ, Beldi G, Banz V
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma - Letter to the editor.
    J Hepatol. 2023 Jan 5:S0168-8278(22)03474-2. doi: 10.1016/j.jhep.2022.
    >> Share

  187. CHEN L, Fan Z, Zhao Y, Yang H, et al
    Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.
    J Hepatol. 2023 Jan 3:S0168-8278(22)03476-6. doi: 10.1016/j.jhep.2022.
    >> Share

  188. ANOLLI MP, Degasperi E, Allweiss L, Sangiovanni A, et al
    A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
    J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.
    >> Share

  189. MOULTON CD, Staite E, Winkley K, Heneghan MA, et al
    The association between liver fibrosis and cognitive impairment in type 2 diabetes.
    J Hepatol. 2023;78:e18-e20.
    >> Share

  190. SHEN Y, Chen H, Wu SD, Jiang W, et al
    Accuracy of transient elastography in assessing fibrosis at diagnosis in individuals with autoimmune liver disease.
    J Hepatol. 2023;78:e33-e34.
    >> Share

  191. BOETTLER T, Krag A, Berg T
    Reply to: "Depiction of alcohol-related liver disease in the EASL International Liver Congress".
    J Hepatol. 2023;78:e38-e39.
    >> Share

  192. TRIPATHI M, Kumar Singh B, Yen PM
    Reply to: "B vitamins for NASH: Use methylcobalamin, not cyanocobalamin".
    J Hepatol. 2023;78:e35-e36.
    >> Share

  193. CARDINALE V, Carpino G, Overi D, Safarikia S, et al
    Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential.
    J Hepatol. 2023;78:165-179.
    >> Share

  194. ABERG F, Byrne CD, Pirola CJ, Mannisto V, et al
    Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease.
    J Hepatol. 2023;78:191-206.
    >> Share

  195. PARK J, Zhao Y, Zhang F, Zhang S, et al
    IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    J Hepatol. 2023;78:45-56.
    >> Share

  196. SPENCE JD
    B vitamins for NASH: Use methylcobalamin, not cyanocobalamin.
    J Hepatol. 2023;78:e34-e35.
    >> Share

  197. MA T, Yu X, Sun M
    Relationship between non-alcoholic fatty liver disease and atrial fibrillation: Assessment of latest evidence.
    J Hepatol. 2023;78:e31-e33.
    >> Share

  198. HADJIHAMBI A, Konstantinou C, Klohs J, Monsorno K, et al
    Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
    J Hepatol. 2023;78:180-190.
    >> Share

  199. GAO X, Lv F, He X, Zhao Y, et al
    Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
    J Hepatol. 2023;78:16-27.
    >> Share

  200. GOODHEART RH, Ayonrinde OT
    Depiction of alcohol-related liver disease in the EASL International Liver Congress.
    J Hepatol. 2023;78:e36-e38.
    >> Share

    December 2022
  201. MCPHAIL MJ, Patel VC, Carter B
    Carvedilol in patients with compensated cirrhosis: the ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
    J Hepatol. 2022 Dec 31:S0168-8278(22)03471-7. doi: 10.1016/j.jhep.2022.
    >> Share

  202. INNES H
    Genetic data not yet a "game-changer" for predicting individualised hepatocellular carcinoma risk.
    J Hepatol. 2022 Dec 30:S0168-8278(22)03467-5. doi: 10.1016/j.jhep.2022.
    >> Share

  203. LIN H, Cheuk-Yan Yiu D, Chin S, Liu K, et al
    Metformin in patients with hepatocellular carcinoma receiving immunotherapy.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03463-8. doi: 10.1016/j.jhep.2022.
    >> Share

  204. CHOI WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, et al
    Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03459-6. doi: 10.1016/j.jhep.2022.
    >> Share

  205. KOERKAMP BG, Clavien PA, Polak WG
    Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?
    J Hepatol. 2022 Dec 23:S0168-8278(22)03327-X. doi: 10.1016/j.jhep.2022.
    >> Share

  206. LEE BP, Dodge JL, Terrault NA
    Liver Transplant for Alcohol-Associated Liver Disease Continues to Rise 2-Years into the COVID-19 Pandemic Especially Among Young Adults.
    J Hepatol. 2022 Dec 22:S0168-8278(22)03460-2. doi: 10.1016/j.jhep.2022.
    >> Share

  207. HARTMANN P, Schnabl B
    Fungal infections and the fungal microbiome in hepatobiliary disorders.
    J Hepatol. 2022 Dec 21:S0168-8278(22)03415-8. doi: 10.1016/j.jhep.2022.
    >> Share

  208. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    Corrigendum to: "PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
    J Hepatol. 2022 Dec 21:S0168-8278(22)03295-0. doi: 10.1016/j.jhep.2022.
    >> Share

  209. ALBILLOS A, Krag A
    Beta-blockers in the era of precision medicine in patients with cirrhosis.
    J Hepatol. 2022 Dec 15:S0168-8278(22)03330-X. doi: 10.1016/j.jhep.2022.
    >> Share

  210. SANYAL AJ, Williams SA, Lavine JE, Tetri B, et al
    Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03326-8. doi: 10.1016/j.jhep.2022.
    >> Share

  211. KENDRE G, Murugesan K, Brummer T, Segatto O, et al
    Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03328-1. doi: 10.1016/j.jhep.2022.
    >> Share

  212. MAK LY, Gane E, Schwabe C, Yoon KT, et al
    A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Dec 10:S0168-8278(22)03320-7. doi: 10.1016/j.jhep.2022.
    >> Share

  213. BAIGES A, Reverter JC, Garcia Pagan JC
    Reply to "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis".
    J Hepatol. 2022 Dec 9:S0168-8278(22)03322-0. doi: 10.1016/j.jhep.2022.
    >> Share

  214. LI Z, Hu Y, Li Q
    More efforts to explore the association between cirrhosis and COVID-19 mortality, and the association between NAFLD and severe COVID-19.
    J Hepatol. 2022 Dec 8:S0168-8278(22)03319-0. doi: 10.1016/j.jhep.2022.
    >> Share

  215. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Erratum to 'Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner' [J Hepatol 77 (2022) 1059-1070].
    J Hepatol. 2022 Dec 2:S0168-8278(22)03141-5. doi: 10.1016/j.jhep.2022.
    >> Share

  216. RUMGAY H, Arnold M, Ferlay J, Lesi O, et al
    Global burden of primary liver cancer in 2020 and predictions to 2040.
    J Hepatol. 2022;77:1598-1606.
    >> Share

  217. MITTEN EK, Baffy G
    Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:1642-1656.
    >> Share

  218. PAFILI K, Kahl S, Mastrototaro L, Strassburger K, et al
    Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease.
    J Hepatol. 2022;77:1504-1514.
    >> Share

  219. MENDEZ-SANCHEZ N, Pal SC
    New terms for fatty liver disease other than MAFLD: Time for a reality check.
    J Hepatol. 2022;77:1716-1717.
    >> Share

  220. BRANDEL V, Schimek V, Gober S, Hammond T, et al
    Hepatectomy-induced apoptotic extracellular vesicles stimulate neutrophils to secrete regenerative growth factors.
    J Hepatol. 2022;77:1619-1630.
    >> Share

  221. TIAN C, Min X, Zhao Y, Wang Y, et al
    MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM.
    J Hepatol. 2022;77:1491-1503.
    >> Share

  222. KIM BK, Tamaki N, Imajo K, Yoneda M, et al
    Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    J Hepatol. 2022;77:1482-1490.
    >> Share

  223. EUROPEAN ASSOCIATION FOR THE S
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
    >> Share

  224. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    >> Share

    November 2022
  225. SUN J, Ding J, Shen Q, Wang X, et al
    Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
    J Hepatol. 2022 Nov 30:S0168-8278(22)03311-6. doi: 10.1016/j.jhep.2022.
    >> Share

  226. THABUT D, Kudo M
    Treatment of portal hypertension in patients with HCC at the era of Baveno VII.
    J Hepatol. 2022 Nov 29:S0168-8278(22)03313-X. doi: 10.1016/j.jhep.2022.
    >> Share

  227. MIESBACH W, Foster GR, Peyvandi F
    Liver-Related Aspects of Gene Therapy for Haemophilia: Call to Action for Collaboration between Haematologists and Hepatologists.
    J Hepatol. 2022 Nov 24:S0168-8278(22)03307-4. doi: 10.1016/j.jhep.2022.
    >> Share

  228. NAHON P, Bamba-Funck J, Layese R, Trepo E, et al
    Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
    J Hepatol. 2022 Nov 22:S0168-8278(22)03294-9. doi: 10.1016/j.jhep.2022.
    >> Share

  229. LOUVET A, Bourcier V, Archambeaud I, d'Alteroche L, et al
    Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
    J Hepatol. 2022 Nov 21:S0168-8278(22)03304-9. doi: 10.1016/j.jhep.2022.
    >> Share

  230. AJMERA V, Cepin S, Tesfai K, Hofflich H, et al
    A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.
    >> Share

  231. CHOI SJ, Choi SH, Kim DW, Kwag M, et al
    Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03297-4. doi: 10.1016/j.jhep.2022.
    >> Share

  232. CHOLANKERIL G, Kramer JR, Chu J, Yu X, et al
    Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03299-8. doi: 10.1016/j.jhep.2022.
    >> Share

  233. LUO L, Yao X, Yang W
    Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
    >> Share

  234. BAJAJ JS
    Albumin for Liver-Brain Outcome Improvement Across Different Situations in Cirrhosis.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03298.
    >> Share

  235. SANYAL AJ, Foucquier J, Younossi ZM, Harrison SA, et al
    Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    J Hepatol. 2022 Nov 11. pii: S0168-8278(22)03293.
    >> Share

  236. CHEN S, Lu Z, Jia H, Yang B, et al
    Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
    J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
    >> Share

  237. SHEN W, Middleton MS, Cunha GM, Delgado TI, et al
    Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    J Hepatol. 2022 Nov 8. pii: S0168-8278(22)03284.
    >> Share

  238. ZHANG X, Song J, Zhang Y, Wen B, et al
    Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis.
    J Hepatol. 2022 Nov 7. pii: S0168-8278(22)03287.
    >> Share

  239. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
    Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
    J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
    >> Share

  240. RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
    >> Share

  241. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients'.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03162.
    >> Share

  242. VAN KLEEF LA, Kavousi M, de Knegt RJ
    Reply to: "Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues".
    J Hepatol. 2022;77:1467-1468.
    >> Share

  243. PETERMANN-ROCHA F, Ho FK, Pell JP
    Reply to: "Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants".
    J Hepatol. 2022;77:1454-1455.
    >> Share

  244. ENGELMANN C, Habtesion A, Hassan M, Kerbert AJ, et al
    Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
    J Hepatol. 2022;77:1325-1338.
    >> Share

  245. ALLEN AM, Therneau TM, Ahmed OT, Gidener T, et al
    Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    J Hepatol. 2022;77:1237-1245.
    >> Share

  246. TRIPATHI M, Singh BK, Zhou J, Tikno K, et al
    Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
    J Hepatol. 2022;77:1246-1255.
    >> Share

  247. JIN B, Du S, Yang H
    HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.
    J Hepatol. 2022;77:1469-1470.
    >> Share

  248. TSAI WC, Yu ML, Dai CY
    Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues.
    J Hepatol. 2022;77:1466-1467.
    >> Share

  249. NAOUMOV NV, Brees D, Loeffler J, Chng E, et al
    Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
    J Hepatol. 2022;77:1399-1409.
    >> Share

  250. HENDRIKX T, Porsch F, Kiss MG, Rajcic D, et al
    Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH.
    J Hepatol. 2022;77:1373-1385.
    >> Share

  251. DIAO YK, Kong QY, Yang T
    HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?
    J Hepatol. 2022;77:1468-1469.
    >> Share

  252. CHEN L, Fan Z, Lv G
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;77:1453-1454.
    >> Share

  253. TRANAH TH, Ballester MP, Carbonell-Asins JA, Jalan R, et al
    Reply to 'The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?'
    J Hepatol. 2022 Nov 1. pii: S0168-8278(22)03161.
    >> Share

    October 2022
  254. SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
    >> Share

  255. NOUREDDIN M, Harrison SA
    NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03159.
    >> Share

  256. CABIBBO G, Bruix J
    Radiological endpoints as surrogates for survival benefit in Hepatocellular Carcinoma trials: all that glitters is not gold.
    J Hepatol. 2022 Oct 30. pii: S0168-8278(22)03155.
    >> Share

  257. LI B, Hong C, Fan Z, Cai S, et al
    Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acutely decompensated cirrhosis.
    J Hepatol. 2022 Oct 26. pii: S0168-8278(22)03144.
    >> Share

  258. PRYKE R, Guha IN
    Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
    J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
    >> Share

  259. NEVENS F, Trauner M, Manns MP
    Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
    J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
    >> Share

  260. LI T, Lu Z
    Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Oct 11. pii: S0168-8278(22)03136.
    >> Share

  261. PERICAS JM, Tacke F, Anstee QM, Di Prospero NA, et al
    Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.
    J Hepatol. 2022 Oct 7. pii: S0168-8278(22)03131.
    >> Share

  262. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    >> Share

  263. BITTENCOURT PL, Oliveira CP, Codes L, Ferraz MLG, et al
    Internet search engines and social media are improving awareness on non-alcoholic fatty liver disease in Brazil.
    J Hepatol. 2022;77:1217-1219.
    >> Share

  264. PEISELER M, Schwabe R, Hampe J, Kubes P, et al
    Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    J Hepatol. 2022;77:1136-1160.
    >> Share


  265. EASL Clinical Practice Guidelines on the management of cystic liver diseases.
    J Hepatol. 2022;77:1083-1108.
    >> Share

  266. DE GOTTARDI A, Sempoux C, Berzigotti A
    Porto-sinusoidal vascular disorder.
    J Hepatol. 2022;77:1124-1135.
    >> Share

  267. VAN KLEEF LA, Lu Z, Arfan Ikram M, de Groot NMS, et al
    Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study.
    J Hepatol. 2022;77:931-938.
    >> Share

  268. STAUFER K, Huber-Schonauer U, Strebinger G, Pimingstorfer P, et al
    Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:918-930.
    >> Share

  269. BASTATI N, Beer L, Ba-Ssalamah A, Poetter-Lang S, et al
    Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
    J Hepatol. 2022;77:1005-1013.
    >> Share

    September 2022
  270. ELFEKI MA, Singal AK
    The possible link between higher ammonia levels associated with non-alcoholic fatty liver related cirrhosis and diabetes: are we missing chronic kidney disease?
    J Hepatol. 2022 Sep 30. pii: S0168-8278(22)03125.
    >> Share

  271. WANG Y, Hu M, Yang H
    Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.
    J Hepatol. 2022 Sep 27. pii: S0168-8278(22)03122.
    >> Share

  272. REINIS J, Petrenko O, Simbrunner B, Hofer BS, et al
    Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03119.
    >> Share

  273. FAGAN A, Gavis EA, Gallagher ML, Mousel T, et al
    A double-blind randomized placebo-controlled trial of albumin in patients with hepatic encephalopathy: HEAL study.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03116.
    >> Share

  274. RIDOLA L, Riggio O
    Ammonia and prognosis of cirrhosis: a new perspective for identifying high risk patients.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03112.
    >> Share

  275. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    >> Share

  276. ZANETTO A, Pelizzaro F, Campello E, Bulato C, et al
    Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03110.
    >> Share

  277. KUDO M, Finn RS, Qin S, Han KH, et al
    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03111.
    >> Share

  278. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    >> Share

  279. MAIWALL R, Deshmukh A, Sarin SK
    Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]".
    J Hepatol. 2022 Sep 13. pii: S0168-8278(22)03069.
    >> Share

  280. PARIKH ND, Tayob N, Singal AG
    Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
    J Hepatol. 2022 Sep 8. pii: S0168-8278(22)03067.
    >> Share

  281. KAZANKOV K, Novelli S, Chatterjee DA, Phillips A, et al
    Evaluation of CirrhoCare(R) - A digital-health solution for home management of patients with cirrhosis.
    J Hepatol. 2022 Sep 7. pii: S0168-8278(22)03066.
    >> Share

  282. PATERNOSTRO R, Kwanten WJ, Reiberger T
    Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
    >> Share

  283. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    >> Share

  284. LUJAMBIO A, Sarobe P
    Metformin keeps CD8(+) T cells active and moving in NASH-HCC immunotherapy.
    J Hepatol. 2022;77:593-595.
    >> Share

  285. MANDORFER M, Scheiner B, Lisman T
    On coagulation in advanced chronic liver disease and the origin of freshwater eels.
    J Hepatol. 2022;77:886-887.
    >> Share

  286. LANGER MM, Eickelmann C, Kleinbongard P, Lange CM, et al
    Impaired mitochondrial complex IV respiration in peripheral blood mononuclear cells discriminates acute-on-chronic liver failure from acute decompensation.
    J Hepatol. 2022;77:874-876.
    >> Share

  287. CHEN ZX, Liu SY, Tong XM
    Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
    J Hepatol. 2022;77:892-893.
    >> Share

  288. GREUTER T, Yaqoob U, Gan C, Jalan-Sakrikar N, et al
    Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo.
    J Hepatol. 2022;77:723-734.
    >> Share

  289. CHOI SE, Hwang Y, Lee SJ, Jung H, et al
    Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice.
    J Hepatol. 2022;77:735-747.
    >> Share

  290. BASELLI GA, Jamialahmadi O, Pelusi S, Ciociola E, et al
    Rare ATG7 genetic variants predispose patients to severe fatty liver disease.
    J Hepatol. 2022;77:596-606.
    >> Share

  291. WABITSCH S, McCallen JD, Kamenyeva O, Ruf B, et al
    Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.
    J Hepatol. 2022;77:748-760.
    >> Share

  292. XIE J, Lu L, Chen Y, Xu L, et al
    A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults.
    J Hepatol. 2022;77:877-879.
    >> Share

  293. BAIGES A, Procopet B, Silva-Junior G, Llop E, et al
    Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03054.
    >> Share

  294. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    >> Share

    August 2022
  295. WHITFIELD JB, Morgan TR, Seth D
    Reply to: External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Aug 30. pii: S0168-8278(22)03055.
    >> Share

  296. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    >> Share

  297. ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
    >> Share

  298. SALEM R, Greten TF
    Interventional radiology meets immuno-oncology for hepatocellular carcinoma.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03003.
    >> Share

  299. LABENZ C, Arslanow A, Lammert F, Galle PR, et al
    Reply to: "an individualized cirrhosis screening strategy might be more cost-effective in the general population".
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)03006.
    >> Share

  300. CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
    Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
    >> Share

  301. BASELLI G, Romeo S, Valenti L
    Reply to: "Lack of hepatic autophagy promotes severity of liver injury but not steatosis": ATG7 genetic variants behave as fatty liver disease progression modifiers.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02992.
    >> Share

  302. KENNEDY L, Carpino G, Owen T, Ceci L, et al
    Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
    >> Share

  303. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    >> Share

  304. JOHN BV, Ferreira RD, Doshi A, Kaplan DE, et al
    Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)03002.
    >> Share

  305. BAILEY AL, Diamond MS
    Hepatopathology of flaviviruses.
    J Hepatol. 2022 Aug 15. pii: S0168-8278(22)00339.
    >> Share

  306. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
    Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
    >> Share

  307. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    >> Share

  308. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
    Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
    J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
    >> Share

  309. GEHRING AJ, MacParland SA
    Intrahepatic T cells with NK-like properties: expanding the repertoire of lymphocytes sensitive to bystander activation.
    J Hepatol. 2022 Aug 12. pii: S0168-8278(22)02985.
    >> Share

  310. ALAZAWI W
    Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
    J Hepatol. 2022;77:290-292.
    >> Share


  311. EASL Clinical Practice Guidelines on haemochromatosis.
    J Hepatol. 2022;77:479-502.
    >> Share

  312. SCHOMERUS G, Leonhard A, Manthey J, Morris J, et al
    The stigma of alcohol-related liver disease and its impact on healthcare.
    J Hepatol. 2022;77:516-524.
    >> Share

  313. BLACK SM, Zhang Z, Han Y, Zeng C, et al
    Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
    J Hepatol. 2022;77:562-563.
    >> Share

  314. BUGIANESI E, Petta S
    NAFLD/NASH.
    J Hepatol. 2022;77:549-550.
    >> Share

  315. BJORNSSON HK, Bjornsson ES
    Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
    J Hepatol. 2022;77:555-556.
    >> Share

  316. ROWE IA, D'Amico G
    Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction.
    J Hepatol. 2022;77:293-295.
    >> Share

  317. JAESCHKE H, Umbaugh DS
    Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
    J Hepatol. 2022;77:560-562.
    >> Share

  318. ABERG F, Luukkonen PK, But A, Salomaa V, et al
    Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score.
    J Hepatol. 2022;77:302-311.
    >> Share

  319. MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
    Can azathioprine prevent infliximab-induced liver injury?
    J Hepatol. 2022;77:553-555.
    >> Share

    July 2022
  320. TRANAH TH, Ballester MP, Carbonell-Asins JA, Ampuero J, et al
    Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
    J Hepatol. 2022 Jul 21. pii: S0168-8278(22)02947.
    >> Share

  321. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    >> Share

  322. NELL P, Kattler K, Feuerborn D, Hellwig B, et al
    Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02943.
    >> Share

  323. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    >> Share

  324. ZHAO S, Liao X, Fan R
    An individualized cirrhosis screening strategy might be more cost-effective in the general population.
    J Hepatol. 2022 Jul 14. pii: S0168-8278(22)02937.
    >> Share

  325. MAIMONE S, Tripodi VF, Mazzeo AT
    Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Jul 7. pii: S0168-8278(22)02926.
    >> Share

  326. FONTANELLAS A, Avila MA
    Hydroxymethylbilane synthase (aka porphobilinogen deaminase): a novel metabolic tumor suppressor gene in hepatocellular carcinoma.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02921.
    >> Share

  327. BARCENA-VARELA M
    Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
    J Hepatol. 2022;77:9-11.
    >> Share

  328. GUO B, Zhou J, Zhao X
    Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
    J Hepatol. 2022;77:260-262.
    >> Share

  329. YU M, Chen Z, Zhou Q, Zhang B, et al
    PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
    J Hepatol. 2022;77:140-151.
    >> Share

  330. MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
    Cigarette smoking and liver diseases.
    J Hepatol. 2022;77:191-205.
    >> Share

  331. CHEN YS, Hung YM, Wei JC
    Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
    J Hepatol. 2022;77:259-260.
    >> Share

  332. MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
    Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;77:249.
    >> Share

    June 2022
  333. VERMA AK, Sharma A, Subramaniyam N, Gandhi CR, et al
    Augmenter of liver regeneration: mitochondrial function and steatohepatitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00413.
    >> Share

  334. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    >> Share

  335. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    >> Share

  336. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    >> Share

  337. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
    >> Share

  338. BEAUFRERE A, Vilgrain V, Paradis V
    Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
    J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.
    >> Share

  339. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    >> Share

  340. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    >> Share

  341. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    >> Share

  342. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
    >> Share

  343. SALEM R, Tselikas L, De Baere T
    Interventional treatment of hepatocellular carcinoma.
    J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.
    >> Share

  344. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    >> Share


  345. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
    J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.
    >> Share

  346. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    >> Share

  347. ANSTEE QM, Castera L, Loomba R
    Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
    J Hepatol. 2022;76:1362-1378.
    >> Share

  348. CALDERARO J, Seraphin TP, Luedde T, Simon TG, et al
    Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
    J Hepatol. 2022;76:1348-1361.
    >> Share

  349. CARACENI P, O'Brien A, Gines P
    Long-term albumin treatment in patients with cirrhosis and ascites.
    J Hepatol. 2022;76:1306-1317.
    >> Share

  350. LISMAN T, Caldwell SH, Intagliata NM
    Haemostatic alterations and management of haemostasis in patients with cirrhosis.
    J Hepatol. 2022;76:1291-1305.
    >> Share

  351. TERRAULT NA, Dufour JF, Schwabe RF, Wong VW, et al
    Breakthroughs in hepatology.
    J Hepatol. 2022;76:1247-1248.
    >> Share

  352. GARDIN A, Remih K, Gonzales E, Andersson ER, et al
    Modern therapeutic approaches to liver-related disorders.
    J Hepatol. 2022;76:1392-1409.
    >> Share

  353. BAJAJ JS, Ng SC, Schnabl B
    Promises of microbiome-based therapies.
    J Hepatol. 2022;76:1379-1391.
    >> Share

  354. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    >> Share

  355. RATZIU V, Francque S, Sanyal A
    Breakthroughs in therapies for NASH and remaining challenges.
    J Hepatol. 2022;76:1263-1278.
    >> Share

    May 2022
  356. VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
    Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
    >> Share

  357. MOLINA L, Zhu J, Trepo E, Bayard Q, et al
    Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00333.
    >> Share

  358. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00335.
    >> Share

  359. POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
    Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
    >> Share

  360. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    >> Share

  361. DING WX, Ni HM, Waguri S, Komatsu M, et al
    Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00330.
    >> Share

  362. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    >> Share

  363. HUSAIN A, Chiu YT, Oi-Lin Ng I
    EFNAs are functional predictors for overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00317.
    >> Share

  364. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    >> Share

  365. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    >> Share

  366. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    >> Share

  367. SUMAZIN P, Peters TL, Sarabia SF, Kim HR, et al
    Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
    J Hepatol. 2022 May 13. pii: S0168-8278(22)00275.
    >> Share

  368. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    >> Share

  369. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    >> Share

  370. SCHEINER B, Pinter M
    Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.
    >> Share

  371. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00265.
    >> Share

  372. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    >> Share

  373. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    >> Share

  374. WANG YZ
    Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.
    >> Share

  375. DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
    The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary.
    J Hepatol. 2022;76:995-1000.
    >> Share

  376. REIG M, Bruix J
    Reply to: "Correspondence on the ".
    J Hepatol. 2022;76:1240-1241.
    >> Share

  377. PETERMANN-ROCHA F, Gray SR, Forrest E, Welsh P, et al
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;76:1021-1029.
    >> Share

  378. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    >> Share

  379. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    >> Share

  380. SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
    Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    J Hepatol. 2022;76:1090-1099.
    >> Share

  381. XU X, Lau WY, Yang T
    The updated BCLC staging system needs further refinement: A surgeon's perspective.
    J Hepatol. 2022;76:1239-1240.
    >> Share

  382. MARJOT T, Ray DW, Tomlinson JW
    Is it time for chronopharmacology in NASH?
    J Hepatol. 2022;76:1215-1224.
    >> Share

  383. MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
    Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
    J Hepatol. 2022;76:1100-1108.
    >> Share

  384. BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
    Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    J Hepatol. 2022;76:1013-1020.
    >> Share

  385. BERRY P, Kotha S
    Improving end of life care in liver disease.
    J Hepatol. 2022;76:1225-1226.
    >> Share

  386. ELHENCE A, Shalimar
    Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: Clear as day or still in fog?
    J Hepatol. 2022;76:1236-1237.
    >> Share

  387. GOVAERE O, Petersen SK, Martinez-Lopez N, Wouters J, et al
    Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:1001-1012.
    >> Share

    April 2022
  388. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    >> Share

  389. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    >> Share

  390. LIU C, Zha Z, Zhou C, Chen Y, et al
    Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
    J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
    >> Share

  391. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    >> Share

  392. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    >> Share

  393. ZHANGYUAN G
    Is beta-catenin mutation in murine hepatocytes sufficient to induce liver tumorigenesis?
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00242.
    >> Share

  394. JIANG X, Fulte S, Deng F, Chen S, et al
    Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00245.
    >> Share

  395. ALKHOURI N, Herring R, Kabler H, Kayali Z, et al
    Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00235.
    >> Share

  396. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00198.
    >> Share

  397. CHUAH S, Lee J, Song Y, Kim HD, et al
    Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00233.
    >> Share

  398. LI C, Ouyang W, Yang T
    The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00228.
    >> Share

  399. CHAPIRO J
    Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00227.
    >> Share

  400. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    >> Share

  401. RUSSO FP, Vigano M, Stock P, Ferrarese A, et al
    HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00175.
    >> Share

  402. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00197.
    >> Share

  403. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
    J Hepatol. 2022 Apr 6. pii: S0168-8278(22)00196.
    >> Share

  404. DEMIR M, Lang S, Hartmann P, Duan Y, et al
    The fecal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:788-799.
    >> Share

  405. MEHAL WZ, Schwabe RF
    A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:765-767.
    >> Share

  406. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    >> Share

  407. BYRNE CD, Newsome PN, Noureddin M
    Why are there no strategies for NAFLD?
    J Hepatol. 2022;76:763-764.
    >> Share

  408. LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
    The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
    J Hepatol. 2022;76:771-780.
    >> Share

  409. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    >> Share

  410. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    >> Share

  411. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    >> Share

    March 2022
  412. BARSCH M, Salie H, Schlaak AE, Zhang Z, et al
    T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00180.
    >> Share

  413. WANG S, Wu Q, Chen T, Su R, et al
    Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00179.
    >> Share

  414. LI D, Yi C, Huang H, Li J, et al
    Hepatocyte specific depletion of Nnmt protects the mice from non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00191.
    >> Share

  415. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    >> Share

  416. ZANETTO A, Campello E, Bulato C, Gavasso S, et al
    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
    J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
    >> Share

  417. JALAN R, Rose CF
    Heretical thoughts into Hepatic Encephalopathy.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00183.
    >> Share

  418. BEAULANT A, Dia M, Pillot B, Chauvin MA, et al
    Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00185.
    >> Share

  419. LIN P, Yang H
    EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00176.
    >> Share

  420. TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
    Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
    >> Share

  421. MAGYAR CTJ, Beldi G, Banz V
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
    >> Share

  422. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
    >> Share

  423. YANG Y, Ouyang J, Zhou Y, Zhou J, et al
    The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00188.
    >> Share

  424. XIONG J, Tian Y
    Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
    >> Share

  425. TRIPODI A
    Cirrhosis. What are all those factor VIII and protein C for?
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
    >> Share

  426. SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
    Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
    J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
    >> Share

  427. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    >> Share

  428. WANG Q, Zhou H, Bu Q, Wei S, et al
    Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
    >> Share

  429. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    >> Share

  430. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
    >> Share

  431. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    >> Share

  432. SINGH SP, Jindal A
    Association of rectal colonisation by MDROs with new infection in cirrhosis.
    J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
    >> Share

  433. SUN X, Wu J, Liu L, Chen Y, et al
    Transcriptional switch of hepatocytes initiates macrophage recruitment and T cell suppression in endotoxemia.
    J Hepatol. 2022 Mar 8. pii: S0168-8278(22)00136.
    >> Share

  434. INNES H, Morling JR, Buch S, Hamill V, et al
    Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
    J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
    >> Share

  435. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    >> Share

  436. LOESCH R, Caruso S, Paradis V, Godard C, et al
    Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
    J Hepatol. 2022 Mar 4. pii: S0168-8278(22)00130.
    >> Share


  437. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
    J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
    >> Share

  438. SPELIOTES EK, George J
    Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
    J Hepatol. 2022;76:498-500.
    >> Share

  439. DING WX, Sancho-Bru P
    SOX9 acts downstream of YAP to decide liver cell fate and tumor types.
    J Hepatol. 2022;76:503-505.
    >> Share

  440. MARTINEZ J, Hernandez-Gea V, Albillos A
    Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleeding".
    J Hepatol. 2022;76:752-753.
    >> Share

  441. SHALTOUT I, Alkandari H, Fouad Y, Hamed AE, et al
    Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;76:739-740.
    >> Share

  442. DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
    Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
    J Hepatol. 2022;76:744-747.
    >> Share

  443. EL-SHABRAWI M, Memon I, Attia D, El-Koofy NM, et al
    The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease.
    J Hepatol. 2022;76:738-739.
    >> Share

  444. LIU D, Zhang Q, Bai P, Zhao J, et al
    Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:740-742.
    >> Share

  445. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    >> Share

  446. ALABSAWY E, Shalimar, Jalan R
    Potential novel approaches to prevent the risk of infection in patients with variceal bleeding.
    J Hepatol. 2022;76:751-752.
    >> Share


  447. Expression of concern: "The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis" by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701-702].
    J Hepatol. 2022;76:758.
    >> Share

  448. GUO B, Guo Y, Nima Q, Feng Y, et al
    Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2022;76:518-525.
    >> Share

  449. REIG M, Forner A, Rimola J, Ferrer-Fabrega J, et al
    BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
    J Hepatol. 2022;76:681-693.
    >> Share

  450. KRONSTEN VT, Tranah TH, Pariante C, Shawcross DL, et al
    Gut-derived systemic inflammation as a driver of depression in chronic liver disease.
    J Hepatol. 2022;76:665-680.
    >> Share

  451. RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
    Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    J Hepatol. 2022;76:536-548.
    >> Share

  452. RATZIU V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al
    EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    J Hepatol. 2022;76:506-517.
    >> Share

  453. LUUKKONEN PK, Qadri S, Ahlholm N, Porthan K, et al
    Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:526-535.
    >> Share

  454. YIP TC, Lee HW, Chan WK, Wong GL, et al
    Asian perspective on NAFLD-associated HCC.
    J Hepatol. 2022;76:726-734.
    >> Share

    February 2022
  455. HUSAIN A, Chiu YT, Sze KM, Ho DW, et al
    Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.
    J Hepatol. 2022 Feb 25. pii: S0168-8278(22)00125.
    >> Share

  456. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00061.
    >> Share

  457. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00126.
    >> Share

  458. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    >> Share

  459. PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
    Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
    >> Share

  460. OLLIVIER-HOURMAND I, Allaire M, Cervoni JP
    Management of portal hypertension in patients treated with Atezolizumab and Bevacizumab for hepatocellular carcinoma.
    J Hepatol. 2022 Feb 16. pii: S0168-8278(22)00079.
    >> Share

  461. SCHEINER B, Pinter M
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy - authors' reply.
    J Hepatol. 2022 Feb 14. pii: S0168-8278(22)00073.
    >> Share

  462. FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
    Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
    >> Share

  463. JEONG J, Tanaka M, Iwakiri Y
    Hepatic lymphatic vascular system in health and disease.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00071.
    >> Share

  464. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    >> Share

  465. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
    J Hepatol. 2022 Feb 9. pii: S0168-8278(22)00026.
    >> Share

  466. ZINGONI A, Banales JM
    PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness.
    J Hepatol. 2022 Feb 8. pii: S0168-8278(22)00070.
    >> Share

  467. ZENG Q, Klein C, Caruso S, Maille P, et al
    Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00031.
    >> Share

  468. SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
    HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
    >> Share

  469. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    >> Share

  470. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    >> Share

  471. ENGELMANN C, Bruns T, Berg T
    Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
    J Hepatol. 2022;76:473-475.
    >> Share

  472. KIM D, Ahmed A
    Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver".
    J Hepatol. 2022;76:477-478.
    >> Share

  473. FOUAD YM, Mendez-Sanchez N, Zheng MH
    One not like the other: The weakness of the blood sugar-MAFLD analogy.
    J Hepatol. 2022;76:482-484.
    >> Share

  474. DE A, Ahmad N, Mehta M, Singh P, et al
    NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
    J Hepatol. 2022;76:475-477.
    >> Share

  475. JINDAL A, Sarin SK
    G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
    J Hepatol. 2022;76:472-473.
    >> Share

  476. WANG YZ
    MAFLD supported by 95.45% participants of CSH is NOT representative.
    J Hepatol. 2022;76:481-482.
    >> Share

  477. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    >> Share

  478. DANA J, Debray D, Beaufrere A, Hillaire S, et al
    Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    J Hepatol. 2022;76:420-434.
    >> Share

  479. MALLET V, Parlati L, Martinino A, Scarano Pereira JP, et al
    Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
    J Hepatol. 2022;76:265-274.
    >> Share

  480. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    >> Share

    January 2022
  481. YANG M, Wu X, Hu J, Wang Y, et al
    COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
    J Hepatol. 2022 Jan 28. pii: S0168-8278(22)00022.
    >> Share

  482. BRUNT EM, Clouston AD, Goodman Z, Guy C, et al
    Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00024.
    >> Share

  483. RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
    Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
    >> Share

  484. LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
    Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
    >> Share

  485. PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
    Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
    >> Share

  486. BUONOMO E, Mei S, Guinn S, Leo I, et al
    Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
    >> Share

  487. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    >> Share

  488. ZHOU HF, Yang W, Zhou WZ
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
    J Hepatol. 2022 Jan 18. pii: S0168-8278(22)00004.
    >> Share

  489. D'AMICO G, Bernardi M, Angeli P
    Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
    >> Share

  490. CRAMER T, Vaupel P
    Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02305.
    >> Share

  491. JAGADISAN B, Dhawan A
    Emergencies in Pediatric hepatology.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02304.
    >> Share

  492. MALLET V, Schwarzinger M
    Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients".
    J Hepatol. 2022;76:229-230.
    >> Share

  493. LONG J, Sang X, Zhao H
    Association of chronic liver disease with the prognosis of COVID-19 patients.
    J Hepatol. 2022;76:228-229.
    >> Share

  494. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    >> Share

  495. SCHUPPAN D, Myneni S, Surabattula R
    Liquid biomarkers for fibrotic NASH - progress in a complex field.
    J Hepatol. 2022;76:5-7.
    >> Share


  496. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".
    J Hepatol. 2022;76:251-252.
    >> Share

  497. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    >> Share

  498. TURON F, Lisman T, Carlos-Garcia-Pagan J
    Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors".
    J Hepatol. 2022;76:227-228.
    >> Share

  499. LI B, He Q, Lu G, Hong C, et al
    Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
    J Hepatol. 2022;76:225-227.
    >> Share

  500. VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
    Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
    J Hepatol. 2022;76:245-246.
    >> Share

  501. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    >> Share

  502. LIU Y, Liu C, Li J, Kim TH, et al
    Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102).
    J Hepatol. 2022;76:248-250.
    >> Share

  503. COREY KE, Pitts R, Lai M, Loureiro J, et al
    ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    J Hepatol. 2022;76:25-33.
    >> Share

  504. DA SILVA LIMA N, Fondevila MF, Novoa E, Buque X, et al
    Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
    J Hepatol. 2022;76:11-24.
    >> Share

  505. VOGEL A, Saborowski A
    Medical therapy of HCC.
    J Hepatol. 2022;76:208-210.
    >> Share

  506. LOOSEN SH, Kostev K, Keitel V, Tacke F, et al
    An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD.
    J Hepatol. 2022;76:247-248.
    >> Share

  507. SINGAL AG, El-Serag HB
    Rational HCC screening approaches for patients with NAFLD.
    J Hepatol. 2022;76:195-201.
    >> Share

  508. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    >> Share

  509. SEKIBA K, Otsuka M, Funato K, Miyakawa Y, et al
    HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
    J Hepatol. 2022;76:53-62.
    >> Share

  510. ZHANG IW, Curto A, Lopez-Vicario C, Casulleras M, et al
    Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.
    J Hepatol. 2022;76:93-106.
    >> Share

  511. GHELFI J, Brusset B, Thony F, Decaens T, et al
    Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
    J Hepatol. 2022;76:216-218.
    >> Share

    December 2021
  512. SCHEINER B, Pinter M
    Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.
    J Hepatol. 2021 Dec 31. pii: S0168-8278(21)02302.
    >> Share

  513. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
    >> Share

  514. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    >> Share

  515. WANG H, Zhang S, Zhang Y, Jia J, et al
    Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
    J Hepatol. 2021 Dec 26. pii: S0168-8278(21)02248.
    >> Share

  516. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    >> Share

  517. SOUNDARARAJAN R, Gupta P
    Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
    J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
    >> Share

  518. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    >> Share

  519. TEY SK, Wong SWK, Tung Chan JY, Mao X, et al
    Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.
    J Hepatol. 2021 Dec 16. pii: S0168-8278(21)02245.
    >> Share

  520. WANG X, Zeldin S, Shi H, Zhu C, et al
    TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02242.
    >> Share

  521. CHENG AL, Qin S, Ikeda M, Galle PR, et al
    Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02241.
    >> Share

  522. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    >> Share

  523. KASSIANIDES C, Dusheiko G, Di Bisceglie A, Hoofnagle JH, et al
    Michael Charles Kew - Frontrunner in Hepatology.
    J Hepatol. 2021 Dec 6. pii: S0168-8278(21)02224.
    >> Share

  524. KADONO K, Kageyama S, Nakamura K, Hirao H, et al
    Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02235.
    >> Share

  525. NACHIT M, Kwanten WJ, Francque S
    Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?"
    J Hepatol. 2021;75:1513-1514.
    >> Share

  526. LUEDDE T, Baumann U, Keitel V
    Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD".
    J Hepatol. 2021;75:1502-1503.
    >> Share

  527. WONG VW, Lazarus JV
    Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
    J Hepatol. 2021;75:1267-1270.
    >> Share

  528. POHL J, Gebauer B, Gebert P, Tacke F, et al
    Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
    J Hepatol. 2021;75:1505-1506.
    >> Share

  529. MATTHEWS C, Cross TJS
    Before we can find an evidence base for HCC surveillance, we need to define our target demographic.
    J Hepatol. 2021;75:1494-1495.
    >> Share

  530. KOTHA S, Berry P
    Multiple investigations for a very common disorder: Finding the right balance in NAFLD.
    J Hepatol. 2021;75:1501-1502.
    >> Share

  531. CADENAS-SANCHEZ C, Idoate F, Villanueva A, Cabeza R, et al
    Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?
    J Hepatol. 2021;75:1511-1513.
    >> Share

  532. NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
    Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    J Hepatol. 2021;75:1292-1300.
    >> Share

  533. IOANNOU GN
    Epidemiology and risk-stratification of NAFLD-associated HCC.
    J Hepatol. 2021;75:1476-1484.
    >> Share

  534. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
    J Hepatol. 2021;75:1420-1433.
    >> Share

  535. HSU CL, Duan Y, Fouts DE, Schnabl B, et al
    Intestinal virome and therapeutic potential of bacteriophages in liver disease.
    J Hepatol. 2021;75:1465-1475.
    >> Share

  536. KIM D, Konyn P, Sandhu KK, Dennis BB, et al
    Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    J Hepatol. 2021;75:1284-1291.
    >> Share

  537. ENGELMANN C, Herber A, Franke A, Bruns T, et al
    Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
    J Hepatol. 2021;75:1346-1354.
    >> Share

  538. GADALETA RM, Moschetta A
    Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
    J Hepatol. 2021;75:1440-1451.
    >> Share

  539. D'AMICO G, Maruzzelli L, Airoldi A, Petridis I, et al
    Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
    J Hepatol. 2021;75:1355-1366.
    >> Share

    November 2021
  540. CABIBBO G, Singal AG
    The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
    J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
    >> Share

  541. LIU Y, Zhuo S, Zhou Y, Ma L, et al
    Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
    >> Share

  542. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    >> Share

  543. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    >> Share

  544. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    >> Share

  545. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    >> Share

  546. HUO TI, Liao JI, Ho SY
    Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
    J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
    >> Share

  547. XU X, Nan Y
    Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
    >> Share

  548. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    >> Share

  549. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    >> Share

  550. COLOMBO M, Barouki R
    Expanding the liver exposome: should hepatologists care about air pollution?
    J Hepatol. 2021 Nov 5. pii: S0168-8278(21)02165.
    >> Share

  551. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    >> Share

  552. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    >> Share

  553. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
    J Hepatol. 2021;75:1247.
    >> Share

  554. GUPTA P, Sharma V, Kalra N
    Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening".
    J Hepatol. 2021;75:1259-1260.
    >> Share

  555. VILLANUEVA C, Bosch J
    Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?"
    J Hepatol. 2021;75:1242-1243.
    >> Share

  556. KUTAIBA N, Ardalan Z
    Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening.
    J Hepatol. 2021;75:1258-1259.
    >> Share

  557. JI Y, Li J, He Q, Zhou L, et al
    Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
    J Hepatol. 2021;75:1243-1245.
    >> Share

  558. CRISTOFERI L, Nardi A, Carbone M
    Transient elastography in chronic liver disease: Beware of the cut-offs!
    J Hepatol. 2021;75:1245-1246.
    >> Share

  559. REICHERT MC, Ripoll C
    First things first! Can bacterial infections be considered as decompensating events per se?
    J Hepatol. 2021;75:1241-1242.
    >> Share

  560. LANGE NF, Radu P, Dufour JF
    Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    J Hepatol. 2021;75:1217-1227.
    >> Share

  561. HAGSTROM H, Simon TG, Roelstraete B, Stephansson O, et al
    Maternal obesity increases the risk and severity of NAFLD in offspring.
    J Hepatol. 2021;75:1042-1048.
    >> Share

  562. RUIZ-BLAZQUEZ P, Pistorio V, Fernandez-Fernandez M, Moles A, et al
    The multifaceted role of cathepsins in liver disease.
    J Hepatol. 2021;75:1192-1202.
    >> Share

  563. SIMON TG, Roelstraete B, Hartjes K, Shah U, et al
    Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
    J Hepatol. 2021;75:1034-1041.
    >> Share

  564. WANG Q, Liang N, Yang T, Li Y, et al
    DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
    J Hepatol. 2021;75:1142-1153.
    >> Share

  565. JALAN R, Gustot T, Fernandez J, Bernal W, et al
    'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
    J Hepatol. 2021;75:1228-1235.
    >> Share

  566. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    >> Share

  567. RASMUSSEN DN, Thiele M, Johansen S, Kjaergaard M, et al
    Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
    J Hepatol. 2021;75:1017-1025.
    >> Share

  568. LI F, Thuluvath PJ
    EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.
    J Hepatol. 2021;75:1096-1103.
    >> Share

    October 2021
  569. CHAO X, Wang S, Fulte S, Ma X, et al
    Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
    J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
    >> Share

  570. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    >> Share

  571. LAN T, Hu Y, Hu F, Li H, et al
    Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
    >> Share

  572. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    >> Share

  573. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    >> Share

  574. SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
    Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
    >> Share

  575. SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
    Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
    >> Share

  576. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
    >> Share

  577. BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
    Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
    J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
    >> Share

  578. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    >> Share

  579. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    >> Share

  580. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    >> Share

  581. FENG MW, Hanley KL, Feng GS
    Androgen receptor, neovascularization and liver cancer metastasis.
    J Hepatol. 2021;75:768-769.
    >> Share

  582. LIN S, Agarwal B, Kumar R, Jalan R, et al
    Defining the prognosis of critically ill patients with alcohol-related liver disease.
    J Hepatol. 2021;75:986-987.
    >> Share

  583. FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
    Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
    J Hepatol. 2021;75:1009-1010.
    >> Share

  584. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    >> Share

  585. CHEN X, Chen S, Pang J, Tang Y, et al
    Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
    J Hepatol. 2021;75:987-989.
    >> Share

  586. LACKNER C, Stauber RE, Davies S, Denk H, et al
    Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.
    J Hepatol. 2021;75:810-819.
    >> Share

  587. YOUNES R, Caviglia GP, Govaere O, Rosso C, et al
    Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:786-794.
    >> Share

  588. GOLABI P, Paik JM, AlQahtani S, Younossi Y, et al
    Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
    J Hepatol. 2021;75:795-809.
    >> Share

  589. SELVARAJ EA, Mozes FE, Jayaswal ANA, Zafarmand MH, et al
    Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    J Hepatol. 2021;75:770-785.
    >> Share

    September 2021
  590. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    >> Share

  591. HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
    TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
    >> Share

  592. GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
    HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
    >> Share

  593. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    >> Share

  594. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    >> Share

  595. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    >> Share

  596. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    >> Share

  597. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    >> Share

  598. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    >> Share

  599. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    >> Share

  600. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    >> Share

  601. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    >> Share

  602. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    >> Share

  603. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    >> Share

  604. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    >> Share

  605. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    >> Share

  606. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    >> Share

  607. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    >> Share

  608. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    >> Share

  609. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    >> Share

  610. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    >> Share

  611. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    >> Share

  612. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    >> Share


  613. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
    J Hepatol. 2021;75:659-689.
    >> Share

  614. YOO T, Joo SK, Kim HJ, Kim HY, et al
    Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:514-523.
    >> Share

  615. CORRADINI E, Buzzetti E, Dongiovanni P, Scarlini S, et al
    Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
    J Hepatol. 2021;75:506-513.
    >> Share

    August 2021
  616. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    >> Share

  617. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    >> Share

  618. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    >> Share

  619. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    >> Share

  620. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    >> Share

  621. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    >> Share

  622. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    >> Share

  623. NACHIT M, Kwanten WJ, Thissen JP, Op De Beeck B, et al
    Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    J Hepatol. 2021;75:292-301.
    >> Share

  624. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    >> Share

  625. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    >> Share

  626. MARTINEZ J, Hernandez-Gea V, Rodriguez-de-Santiago E, Tellez L, et al
    Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
    J Hepatol. 2021;75:342-350.
    >> Share

  627. YANG Y, Sangwung P, Kondo R, Jung Y, et al
    Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    J Hepatol. 2021;75:377-386.
    >> Share

    July 2021
  628. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    >> Share

  629. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    >> Share

  630. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    >> Share

  631. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    >> Share

  632. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    >> Share

  633. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    >> Share

  634. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    >> Share

  635. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    >> Share

  636. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    >> Share

  637. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    >> Share

  638. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    >> Share

  639. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    >> Share

  640. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    >> Share

  641. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    >> Share

  642. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    >> Share

  643. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    >> Share

  644. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    >> Share

  645. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    >> Share

  646. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    >> Share

  647. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    >> Share

  648. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    >> Share

  649. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    >> Share

  650. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    >> Share

  651. KREMOSER C
    FXR agonists for NASH: How are they different and what difference do they make?
    J Hepatol. 2021;75:12-15.
    >> Share

  652. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    >> Share

  653. BOSCH J
    Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
    J Hepatol. 2021;75:248-249.
    >> Share

  654. STAUBER RE, Scharnagl H, Marsche G
    Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
    J Hepatol. 2021;75:245-246.
    >> Share

  655. SIMBRUNNER B, Costa D, Reiberger T
    Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
    J Hepatol. 2021;75:234-236.
    >> Share

  656. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    >> Share

  657. WEN X, Tong J, Yao M, Hu J, et al
    Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
    J Hepatol. 2021;75:243-245.
    >> Share

  658. WANG X, Luo X, Yang L
    Achieving an effective pressure reduction after TIPS: The need for a new target.
    J Hepatol. 2021;75:246-248.
    >> Share

  659. FERRARESE A, Plebani M, Frigo AC, Burra P, et al
    Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
    J Hepatol. 2021;75:232-234.
    >> Share

  660. BEUERS U
    EASL recognition award recipient 2021: Prof. Dieter Haussinger.
    J Hepatol. 2021;75:7-9.
    >> Share

  661. ROMERO-GOMEZ M
    EASL international recognition award recipient 2021: Prof. Dr. Nahum Mendez-Sanchez.
    J Hepatol. 2021;75:10-11.
    >> Share

  662. MENDEZ-SANCHEZ N, Diaz-Orozco L, Cordova-Gallardo J
    Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
    J Hepatol. 2021;75:221-222.
    >> Share

  663. PETERS L, Burkert S, Gruner B
    Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.
    J Hepatol. 2021;75:202-218.
    >> Share

  664. SIMON J, Goikoetxea-Usandizaga N, Serrano-Macia M, Fernandez-Ramos D, et al
    Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.
    J Hepatol. 2021;75:34-45.
    >> Share

  665. LIU C, Zhou B, Meng M, Zhao W, et al
    FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:150-162.
    >> Share

  666. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    >> Share

  667. GUSTOT T, Stadlbauer V, Laleman W, Alessandria C, et al
    Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
    J Hepatol. 2021;75 Suppl 1:S36-S48.
    >> Share

  668. MOREAU R, Gao B, Papp M, Banares R, et al
    Acute-on-chronic liver failure: A distinct clinical syndrome.
    J Hepatol. 2021;75 Suppl 1:S27-S35.
    >> Share

  669. BURRA P, Samuel D, Sundaram V, Duvoux C, et al
    Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
    J Hepatol. 2021;75 Suppl 1:S178-S190.
    >> Share

  670. BERNAL W, Karvellas C, Saliba F, Saner FH, et al
    Intensive care management of acute-on-chronic liver failure.
    J Hepatol. 2021;75 Suppl 1:S163-S177.
    >> Share

    June 2021
  671. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    >> Share

  672. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    >> Share

  673. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    >> Share

  674. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    >> Share

  675. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    >> Share

  676. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    >> Share

  677. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    >> Share

  678. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    >> Share

  679. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    >> Share

  680. FLEMMING JA, Velez MP
    The ART of medicine: Counselling women with liver disease about assisted reproductive technology.
    J Hepatol. 2021;74:1283-1285.
    >> Share

  681. KUMAR R, Jalan R
    Reply to: "Failure to control variceal bleeding: Definition matters".
    J Hepatol. 2021;74:1492-1493.
    >> Share

  682. BAIGES A, Bureau C, Garcia-Pagan JC
    Failure to control variceal bleeding: Definition matters.
    J Hepatol. 2021;74:1491-1492.
    >> Share

  683. BERNAL W, McPhail MJ
    Acute liver failure.
    J Hepatol. 2021;74:1489-1490.
    >> Share

  684. GILGENKRANTZ H, Mallat A, Moreau R, Lotersztajn S, et al
    Targeting cell-intrinsic metabolism for antifibrotic therapy.
    J Hepatol. 2021;74:1442-1454.
    >> Share

  685. BRUIX J
    Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.
    J Hepatol. 2021;74:1483-1488.
    >> Share

  686. BETTINGER D, Sturm L, Pfaff L, Hahn F, et al
    Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
    J Hepatol. 2021;74:1362-1372.
    >> Share

  687. CADOUX M, Caruso S, Pham S, Gougelet A, et al
    Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness.
    J Hepatol. 2021;74:1386-1397.
    >> Share

  688. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    >> Share

  689. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
    Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    J Hepatol. 2021;74:1355-1361.
    >> Share

    May 2021
  690. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    >> Share

  691. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    >> Share

  692. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    >> Share

  693. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    >> Share

  694. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    >> Share

  695. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    >> Share

  696. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    >> Share

  697. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    >> Share

  698. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    >> Share

  699. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    >> Share

  700. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    >> Share

  701. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    >> Share

  702. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    >> Share

  703. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    >> Share

  704. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    >> Share

  705. JOHNSON PJ
    In search of an evidence base for HCC surveillance: Purity or pragmatism?
    J Hepatol. 2021;74:1025-1027.
    >> Share

  706. ARROYO V, Fernandez J, Moreau R
    Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".
    J Hepatol. 2021;74:1265-1267.
    >> Share

  707. COENRAAD MJ, Artru F
    Amino acids in acute-on-chronic liver failure: Another piece of the puzzle?
    J Hepatol. 2021;74:1015-1017.
    >> Share

  708. ESLAM M, George J
    MAFLD: Now is the time to capitalize on the momentum.
    J Hepatol. 2021;74:1262-1263.
    >> Share

  709. FOUAD Y, Gomaa A, Semida N, Ghany WA, et al
    Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
    J Hepatol. 2021;74:1254-1256.
    >> Share

  710. ALEM SA, Gaber Y, Abdalla M, Said E, et al
    Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
    J Hepatol. 2021;74:1261-1262.
    >> Share

  711. KASPER P, Martin A, Lang S, Demir M, et al
    Hypertension in NAFLD: An uncontrolled burden.
    J Hepatol. 2021;74:1258-1260.
    >> Share

  712. SPEARMAN CW, Desalegn H, Ocama P, Awuku YA, et al
    The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
    J Hepatol. 2021;74:1256-1258.
    >> Share

  713. ZHANG Y, Lu Z, Zeng W, Zhao J, et al
    Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.
    J Hepatol. 2021;74:1250-1253.
    >> Share

  714. ZACCHERINI G, Aguilar F, Caraceni P, Claria J, et al
    Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
    J Hepatol. 2021;74:1117-1131.
    >> Share

  715. WANG T, Chen K, Yao W, Zheng R, et al
    Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
    J Hepatol. 2021;74:1038-1052.
    >> Share

    April 2021
  716. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    >> Share

  717. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    >> Share

  718. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    >> Share

  719. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    >> Share

  720. BELLI LS, Duvoux C, Artzner T, Bernal W, et al
    Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
    >> Share

  721. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    >> Share

  722. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    >> Share

  723. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    >> Share

  724. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    >> Share

  725. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    >> Share

  726. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    >> Share

  727. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    >> Share

  728. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    >> Share

  729. DESSEIN A
    Clinical utility of polygenic risk scores for predicting NAFLD disorders.
    J Hepatol. 2021;74:769-770.
    >> Share

  730. COSTA D, Simbrunner B, Reiberger T
    Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease".
    J Hepatol. 2021;74:1000-1001.
    >> Share

  731. HOBEIKA C, Fuks D
    Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:987-988.
    >> Share

  732. HEGARTY R, Singh S, Bansal S, Fitzpatrick E, et al
    NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.
    J Hepatol. 2021;74:991-992.
    >> Share

  733. ESLAM M, Ratziu V, George J
    Yet more evidence that MAFLD is more than a name change.
    J Hepatol. 2021;74:977-979.
    >> Share

  734. ESLAM M, George J
    MAFLD: A holistic view to redefining fatty liver disease.
    J Hepatol. 2021;74:983-985.
    >> Share

  735. ESLAM M, George J
    MAFLD: A game changer redefining fatty liver disease for adults and children.
    J Hepatol. 2021;74:992-994.
    >> Share

  736. AMPUERO J, Gallego-Duran R, Romero-Gomez M
    Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    J Hepatol. 2021;74:971-972.
    >> Share

  737. ZHENG KI, Sun DQ, Jin Y, Zhu PW, et al
    Clinical utility of the MAFLD definition.
    J Hepatol. 2021;74:989-991.
    >> Share

  738. DEBNATH P, Rathi P
    Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease.
    J Hepatol. 2021;74:999-1000.
    >> Share

  739. MORENO C, Sheron N, Tiniakos D, Lackner C, et al
    "Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls.
    J Hepatol. 2021;74:979-982.
    >> Share

  740. BAFFY G
    Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'.
    J Hepatol. 2021;74:988.
    >> Share

  741. XIA M, Zeng H, Wang S, Tang H, et al
    Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.
    J Hepatol. 2021;74:974-977.
    >> Share

  742. LIU M, Sun L, Mao Y
    The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    J Hepatol. 2021;74:970-971.
    >> Share

  743. SINGH SP, Anirvan P, Reddy KR, Conjeevaram HS, et al
    Non-alcoholic fatty liver disease: Not time for an obituary just yet!
    J Hepatol. 2021;74:972-974.
    >> Share

  744. PONIACHIK J, Roblero JP, Urzua A, Cattaneo M, et al
    A new definition for non-alcoholic fatty liver disease.
    J Hepatol. 2021;74:982-983.
    >> Share

  745. RUSSOLILLO N, Aldrighetti L, Guglielmi A, Giuliante F, et al
    Correspondence on "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:985-986.
    >> Share

  746. RIMASSA L, Personeni N, Czauderna C, Foerster F, et al
    Systemic treatment of HCC in special populations.
    J Hepatol. 2021;74:931-943.
    >> Share

  747. COSTA D, Simbrunner B, Jachs M, Hartl L, et al
    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    J Hepatol. 2021;74:819-828.
    >> Share

    March 2021
  748. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    >> Share

  749. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    >> Share

  750. LUJAMBIO A, Maina F
    Turning up our understanding of liver cancer by a notch.
    J Hepatol. 2021;74:502-504.
    >> Share

  751. JOYE R, Lador F, Aggoun Y, Farhat N, et al
    Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    J Hepatol. 2021;74:742-747.
    >> Share

  752. HEINRICH S, Craig AJ, Ma L, Heinrich B, et al
    Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
    J Hepatol. 2021;74:700-715.
    >> Share

  753. MOZZANEGA B
    Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
    J Hepatol. 2021;74:750-751.
    >> Share

  754. CHAND D, Mohr F, McMillan H, Tukov FF, et al
    Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    J Hepatol. 2021;74:560-566.
    >> Share

  755. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    >> Share

    February 2021
  756. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    >> Share

  757. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    >> Share

  758. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    >> Share

  759. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    >> Share

  760. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    >> Share

  761. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    >> Share

  762. HERNAEZ R, Kanwal F
    Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
    J Hepatol. 2021;74:477.
    >> Share

  763. GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
    The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
    J Hepatol. 2021;74:475-476.
    >> Share

  764. MANCO R, Itzkovitz S
    Liver zonation.
    J Hepatol. 2021;74:466-468.
    >> Share

  765. SAWATZKI M, Guller U, Gusewell S, Husarik DB, et al
    Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.
    J Hepatol. 2021;74:419-427.
    >> Share

  766. WINKLER M, Staniczek T, Kurschner SW, Schmid CD, et al
    Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.
    J Hepatol. 2021;74:380-393.
    >> Share

  767. WONG F, Piano S, Singh V, Bartoletti M, et al
    Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.
    J Hepatol. 2021;74:330-339.
    >> Share

    January 2021
  768. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    >> Share

  769. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    >> Share

  770. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
    CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
    >> Share

  771. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    >> Share

  772. FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
    NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
    J Hepatol. 2021;74:241-242.
    >> Share

  773. WU Y, Kumar R, Huang J, Wang M, et al
    FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
    J Hepatol. 2021;74:247-248.
    >> Share

  774. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    >> Share

  775. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
    J Hepatol. 2021;74:248-249.
    >> Share

  776. SAVALE L, Sitbon O
    Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
    J Hepatol. 2021;74:238-239.
    >> Share

  777. KOLHE K, Tripathi DM, Kaur S
    Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
    J Hepatol. 2021;74:237-238.
    >> Share

  778. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    >> Share

  779. COZMESCU AC, Counsell J, Gissen P
    Gene therapies targeting the liver.
    J Hepatol. 2021;74:235-236.
    >> Share

  780. BOSCH J
    Small diameter shunts should lead to safe expansion of the use of TIPS.
    J Hepatol. 2021;74:230-234.
    >> Share

  781. DWYER BJ, Macmillan MT, Brennan PN, Forbes SJ, et al
    Cell therapy for advanced liver diseases: Repair or rebuild.
    J Hepatol. 2021;74:185-199.
    >> Share

  782. TEO K, Abeysekera KWM, Adams L, Aigner E, et al
    rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
    J Hepatol. 2021;74:20-30.
    >> Share

    October 2020
  783. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    >> Share

  784. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    >> Share

    September 2020
  785. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    >> Share

  786. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    >> Share

    August 2020
  787. YOSHIZUMI T, Itoh S, Shimokawa M, Inokuchi S, et al
    Simultaneous splenectomy improves outcomes after adult living donor liver transplantation.
    J Hepatol. 2020 Aug 19. pii: S0168-8278(20)30547.
    >> Share

  788. LINE PD, Dueland S
    Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30539.
    >> Share

    July 2020
  789. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    >> Share

    May 2020
  790. GULFO J, Rotondo F, de Leon CGA, Cornide-Petronio ME, et al
    FGF15 improves outcomes after brain dead donor liver transplantation with steatotic and non-steatotic grafts in rats.
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30299.
    >> Share

  791. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    >> Share

    April 2020
  792. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    >> Share

    March 2020
  793. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    >> Share

  794. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    >> Share

  795. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    >> Share

  796. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    >> Share

    February 2020
  797. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    >> Share

  798. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    >> Share

    January 2020
  799. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    >> Share

  800. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    >> Share

  801. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    >> Share

    December 2019
  802. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    >> Share

  803. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    >> Share

  804. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    >> Share

    November 2019
  805. CHIEW AL, James LP, Isbister GK, Pickering JW, et al
    Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
    J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
    >> Share

  806. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    >> Share

    October 2019
  807. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    >> Share

  808. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    >> Share

  809. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016